Metreleptin
Top View
- American Diabetes Association 2008 Annual Meeting
- INN Working Document 05.179 Update December 2010
- Medicines in Development for Diabetes
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- CDER List of Licensed Biological Products With
- Glycomark Compendium of Evidence
- Myalept (Metreleptin)
- Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs
- Self-Administered Specialty Drug List
- Metreleptin for Subcutaneous Injection 11.25 Mg “Shionogi” [Non-Proprietary Name] Metreleptin (Genetical Recombination) (JAN*) [Applicant] Shionogi & Co., Ltd
- Myalept® (Metreleptin)
- NYS Medicaid Fee-For-Service Preferred Drug List PREFERRED DRUG LIST – TABLE of CONTENTS I
- Myalepta, INN-Metreleptin
- Premium Value
- Clinical Diabetes/Therapeutics
- Glucagon-Like Peptide-1 Receptor Co-Agonists for Treating Metabolic Disease
- Astrazeneca Sharps Disposal Plan
- HHS Template for Reports, with Instructions